NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

64 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-20

Study Completion Date

2024-01-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will provide insight into whether a nutritional supplement, nicotinamide riboside (NR), improves memory and brain blood flow in older adults with low memory abilities. Overall, this project has the potential to identify a novel, safe and cost-effective strategy for decreasing age-related memory loss.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia

NCT04430517

Mild Cognitive Impairment Mild Alzheimer Disease

RECRUITING EARLY_PHASE1

Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease

NCT00013923

Alzheimer Disease

COMPLETED PHASE2

Sirtuin-NAD Activator in Alzheimer's Disease

NCT05040321

Alzheimer's Disease (Incl Subtypes) Dementia

RECRUITING PHASE1/PHASE2

Nicotinamide as an Early Alzheimer's Disease Treatment

NCT03061474

Alzheimer's Disease Mild Cognitive Impairment

COMPLETED PHASE2

The Memory and Cognitive Performance Study

NCT04025255

Cognitive Function Memory Brain Health

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mild Cognitive Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Double-blind

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

placebo

Nicotinamide Riboside

Niagen® (ChromaDex, Inc.) 500 mg, twice daily

Group Type EXPERIMENTAL

Niagen®

Intervention Type DRUG

250 mg capsules (4 capsules daily)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Niagen®

250 mg capsules (4 capsules daily)

Intervention Type DRUG

Placebo

placebo

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

nicotinamide riboside chloride

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Cognitive function scores consistent with amnestic mild cognitive impairment based on pre-screening evaluation;
* age 60-90 years;
* MMSE score \>24 at time of initial consent;

Exclusion Criteria

* blood chemistries indicative of abnormal renal, liver, thyroid and adrenal function; estimated glomerular filtration rate using the MDRD prediction equation must be \>30 ml/min/1.73 m2;
* any clinically significant abnormal blood chemistry values as determined by the research nurse or NMPCC nurse practitioner;
* major psychiatric disorder (e.g. schizophrenia, bipolar disorder, major depression within past two years);
* neurological or autoimmune conditions affecting cognition (e.g. Parkinson's disease, epilepsy, multiple sclerosis, mild or severe traumatic brain injury, large vessel infarct);
* concussion within last 2 years and ≥ 3 lifetime concussions;
* current systemic medical illnesses (e.g. cardiovascular disease, cancer, renal failure);
* prior history of any type of cancer;
* substance abuse or dependence (DSM-V criteria);
* current use of medications used to treat dementia (e.g., anticholinesterase drugs) or other drugs likely to affect cognition (e.g., anticholinergic drugs, long-acting benzodiazepines);
* claustrophobia, metal implants, pacemaker or other factors affecting feasibility and/or safety of MRI scanning\*;
* current smoking (including marijuana) within the past 3 months;
* hospitalization as a result of COVID-19

Minimum Eligible Age

60 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No